Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by Vetr from a “strong-buy” rating to a “buy” rating in a report released on Monday. They presently have a $21.73 target price on the stock. Vetr‘s target price suggests a potential upside of 12.47% from the stock’s previous close.
TEVA has been the topic of a number of other research reports. ValuEngine raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Tuesday, December 5th. Wells Fargo & Co reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Saturday, November 25th. Zacks Investment Research downgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research note on Friday, January 12th. Credit Suisse Group raised shares of Teva Pharmaceutical Industries from an “underperform” rating to a “neutral” rating and lifted their price target for the stock from $8.00 to $20.00 in a research note on Friday, December 15th. Finally, UBS Group set a $20.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Monday, December 18th. Ten research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $20.81.
Teva Pharmaceutical Industries (NYSE:TEVA) opened at $19.32 on Monday. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $34.51. The company has a quick ratio of 0.58, a current ratio of 0.86 and a debt-to-equity ratio of 1.91. The company has a market cap of $19,530.00, a price-to-earnings ratio of -1.12, a PEG ratio of 1.66 and a beta of 0.65.
In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 5,050 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $19.68, for a total transaction of $99,384.00. Following the completion of the transaction, the executive vice president now directly owns 44,517 shares of the company’s stock, valued at approximately $876,094.56. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders have sold 7,636 shares of company stock valued at $149,390. 7.10% of the stock is owned by company insiders.
A number of hedge funds have recently made changes to their positions in TEVA. Two Sigma Advisers LP acquired a new position in Teva Pharmaceutical Industries during the 4th quarter worth $118,487,000. Franklin Resources Inc. grew its holdings in Teva Pharmaceutical Industries by 8.2% during the 4th quarter. Franklin Resources Inc. now owns 79,488,139 shares of the company’s stock worth $1,506,309,000 after acquiring an additional 6,009,897 shares in the last quarter. OppenheimerFunds Inc. acquired a new position in Teva Pharmaceutical Industries during the 4th quarter worth $69,418,000. Macquarie Group Ltd. grew its holdings in Teva Pharmaceutical Industries by 350.3% during the 3rd quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock worth $77,587,000 after acquiring an additional 3,429,448 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI grew its holdings in Teva Pharmaceutical Industries by 116.2% during the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 2,799,192 shares of the company’s stock worth $53,045,000 after acquiring an additional 1,504,349 shares in the last quarter. 58.22% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://weekherald.com/2018/03/14/teva-pharmaceutical-industries-teva-rating-lowered-to-buy-at-vetr.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.